The neurologist at Mayo Clinic in Phoenix, Arizona, detailed the importance of further studies of FDA approved medications in different patient populations.
The neurologist at Mayo Clinic in Phoenix, Arizona, discussed the growing variety of treatment options and the progress the migraine community has made on the management of this disease.
The Medtronic device is the only DBS system that is eligible to be used for both 3T and 1.5T full-body MRI scans, with the first implant procedure scheduled at Mayo Clinic.
The neurologist at Mayo Clinic in Phoenix, Arizona, detailed whether her and colleagues recent study results on ubrogepant aligned with previous study findings.
Consistent pain relief from all attacks was reported by 27% of patients treated with ubrogepant and 73% experienced relief from at least 1 attack.
The director of pediatric epilepsy and professor of neurology at Mayo Clinic detailed how care for patients with epilepsy has changed during the COVID-19 pandemic.
The director of pediatric epilepsy and professor of neurology at Mayo Clinic details the rampant acceleration of telemedicine and how her practice is adjusting to the COVID-19 pandemic.
The assistant professor of Neurology, Concussion and Headache Medicine divisions, Mayo Clinic, Scottsdale, Arizona discussed the evolving migraine treatment landscape and how they have been incorporated into her practice.
